Skip to content
Open access

Long-term outcomes and treatment cessation in patients with response to first-line treatment of metastatic prostate cancer

Sep 2026 · The Oncologist · Vol 31 · 0 citations · 10 references
Medicine

Abstract

Abstract Background and objective Approximately one-third of men with metastatic prostate cancer die from causes other than prostate cancer. Little is known about the long-term outcomes of men with metastatic prostate cancer, in particular those who do not develop androgen pathway resistance. The objective of this study is to describe those with long-term survival and disease response to initial therapy and their clinical outcomes. Methods This is a single-institution, retrospective study of patients with metastatic hormone-sensitive prostate cancer diagnosed prior to January 1, 2019 and alive as of December 31, 2024. Clinical and demographic features are described at baseline and follow-up, with outcomes after treatment cessation. Key findings and limitations One hundred and forty-five patients were included with a median age at diagnosis of 61 years. Fifty-one patients (35.2%) had metastatic disease at diagnosis, and 108 (74.5%) had bone metastases at the time of metastatic disease. The median follow-up from the date of metastatic disease was 8.4 years. Eighty-nine (61.4%) patients continued to have disease response to initial therapy after a median of 8.8 years. Thirty-two patients stopped therapy, and of those, 25 recovered testosterone, with 11 patients continuing to have an undetectable prostate-specific antigen (8% of total cohort and 34% of those who stopped therapy). Conclusions and clinical implications In this cohort, most patients did not have further progression of disease, and 8% of patients had durable treatment-free remissions. Further research is needed on treatment cessation in men with exceptional responses to androgen deprivation therapy.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.